Zerbo Ilara R, Zijderveld Steven A, de Boer Anje, Bronckers Antonius L J J, de Lange Gert, ten Bruggenkate Christiaan M, Burger Elizabeth H
Department of Oral Cell Biology, ACTA, Amsterdam, The Netherlands.
Clin Oral Implants Res. 2004 Dec;15(6):724-32. doi: 10.1111/j.1600-0501.2004.01055.x.
Tricalcium phosphate (TCP) has been historically a well-accepted material for bone augmentation. We examined the use of a porous beta-TCP (100%) in a split mouth model for sinus floor augmentation. Five patients were treated bilaterally, receiving 1-2 mm-sized beta-TCP particles (Cerasorb) on one side (test side) and autologous chin bone particles on the other (control) side. Four other patients were treated with a unilateral sinus floor augmentation using 100% beta-TCP (no controls). Biopsies of the augmented sites were taken at 6 months. Histomorphometry measurements were carried out in order to quantify bone augmentation at test and control sides. The average bone volume (BV) formed in the augmented sinus at the control side was 41% (32-56%) and 17% (9-27%) in the test side when all nine patients were included (statistically significant, P=0.04). When only the five bilateral patients were included, mean BV of the test side was 19% (13-27%), which was also significantly different from the control side (P=0.009). Osteoid formation tended to be higher in the test side biopsies (1.3%) than in the controls (0.3%) (marginally significant, P=0.1), indicating ongoing bone formation in the TCP material. The amount of lamellar bone at the test side was less than half the amount in the control side, indicating that remodelling had only recently started in the TCP-augmented side. The resorption surface, however, did not differ significantly between the two sides. These histological results indicate that Cerasorb is an acceptable bone substitute material for augmentation of the maxillary sinus. Due to the osteoconductive, but not osteoinductive properties of this material, the rate of bone formation is somewhat delayed in comparison to autologous bone.
磷酸三钙(TCP)一直以来都是一种被广泛认可的用于骨增量的材料。我们在双侧上颌窦底提升的分口模型中研究了多孔β-TCP(100%)的应用。5名患者接受了双侧治疗,一侧(试验侧)植入1-2毫米大小的β-TCP颗粒(Cerasorb),另一侧(对照侧)植入自体颏骨颗粒。另外4名患者接受了单侧上颌窦底提升术,使用100%的β-TCP(无对照)。在6个月时对提升部位进行活检。进行组织形态计量学测量以量化试验侧和对照侧的骨增量。当纳入所有9名患者时,对照侧上颌窦提升部位形成的平均骨体积(BV)为41%(32%-56%),试验侧为17%(9%-27%)(具有统计学意义,P=0.04)。当仅纳入5名双侧治疗的患者时,试验侧的平均BV为19%(13%-27%),与对照侧也有显著差异(P=0.009)。试验侧活检标本中的类骨质形成倾向于高于对照侧(1.3%比0.3%)(边缘显著,P=0.1),表明TCP材料中正在进行骨形成。试验侧的板层骨量不到对照侧的一半,表明TCP提升侧的重塑最近才开始。然而,两侧的吸收表面没有显著差异。这些组织学结果表明,Cerasorb是一种可接受的用于上颌窦提升的骨替代材料。由于这种材料具有骨传导性但无骨诱导性,与自体骨相比,骨形成速率有所延迟。